Our current understanding of biomarkers and the progression of Alzheimer’s

There is much work to be done to improve our understanding of the role that biomarkers play in the clinical symptoms of Alzheimer’s disease. Michelle Mielke, PhD from the Mayo Clinic, Rochester, MN speaks to us about how biomarkers can be unreliable in predicting which patients will develop the disease, and gives some examples of key areas where future research could focus. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) in London, UK.

Share this video